GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
540
c/tirzepatide·posted 1 months ago by u/copay_card_cc

what would you tell week-1 you about GIP

Question Clean Column ×3

Trying to get a straight answer on this: what would you tell week-1 you about GIP.

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.

795 up / 255 down76% upvoted28 commentsid oyi9xv1 Jun 2026

28 comments

23 in this archive, depth 5

best — the order this archive was captured in

u/quiet_moderatorMOD138 points·1 months ago

This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.

replysharereportpermalink
u/throwaway_wl2026112 points·1 months ago·edited

This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.

Saving this one. It is the clearest statement of the stall problem I have read here.

replysharereportpermalink
u/copay_card_ccOP-29 points·1 months ago

This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.

quiet_moderator is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.

replysharereportpermalink
u/copay_card_ccOP1 point·1 months ago

Correction to my own post above — I said 15mg and I have been on 2.5mg since the spring. Same argument, wrong number.

replysharereportpermalink
u/marit_sandvik1 point·1 months ago·edited

Correction to my own post above — I said 15mg and I have been on 2.5mg since the spring.

This. The step interval is a floor, and reading it as a timetable is the most expensive mistake in the thread.

replysharereportpermalink
u/search_before_post1 point·1 months ago

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

replysharereportpermalink
u/mikkel_ogunleye61 points·1 months ago·edited

This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.

replysharereportpermalink
u/search_before_post64 points·1 months ago

The step schedule question, answered properly, because it comes up weekly.

The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.

What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.

replysharereportpermalink
u/throwaway_titration52 points·1 months ago

week 10 is early to draw any conclusion at all

replysharereportpermalink
u/copay_card_ccOP32 points·1 months ago

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

replysharereportpermalink
u/coring_the_stopper17 points·1 months ago·edited

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

replysharereportpermalink
u/vito_chowdhury12 points·1 months ago

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

replysharereportpermalink
u/emil_barros51 points·1 months ago

Not sure that follows. You went up a step and changed your training in the same fortnight.

replysharereportpermalink
u/discount_math_dm30 points·1 months ago

What is the waist doing? That is usually the number still moving during a scale stall.

replysharereportpermalink
u/b12_baseline7 points·1 months ago

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

replysharereportpermalink
u/georgi_chowdhury25 points·1 months ago

Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.

replysharereportpermalink
u/tidy_vialdrawer_pls7 points·1 months ago

Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.

replysharereportpermalink
u/line_petrov4 points·1 months ago

Did you come to this from sema, and if so how long was the gap?

replysharereportpermalink
u/certified_referenceQC1 point·1 months ago

the trials titrated on a calendar, real people titrate on symptoms

replysharereportpermalink
u/search_before_post2 points·1 months ago

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

replysharereportpermalink
u/tarek_kirchner15 points·1 months ago

the early fullness profile is genuinely gentler than people expect coming from sema

replysharereportpermalink
[deleted]6 points·1 months ago

[deleted]

replysharereportpermalink
u/tarek_lokken2 points·1 months ago

sulphur burps are the signature complaint and they are not dangerous

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.